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In the liver, the hepatocyte mass is kept stable through a tight balance between hepatocyte
death and proliferation that is frequently lost upon acute or chronic liver injury. Wuestefeld et al.
(2013) now identify a potentially druggable target that enhances hepatocyte proliferation and
promotes liver regeneration, thereby preventing liver failure.Hepatocytes can proliferate extensively,
which is critical for liver homeostasis
and, even more so, liver regeneration. In
severe liver diseases, however, excessive
hepatocyte death may not be sufficiently
compensated by normal hepatocyte
proliferation, leading to loss of liver func-
tion and ultimately multiorgan failure.
Thus, strategies for identifying druggable
targets that could enhance liver regenera-
tion are of great therapeutic value. Toward
this aim, Wuestefeld et al. (2013) per-
formed anRNA interference (RNAi) screen
in mouse models of subacute and chronic
liver injury knocking down 301 putative
tumor suppressor genes previously iden-
tified in human hepatocellular carcinomas
(Zender et al., 2008). They identify a gene
whose suppression leads to a robust
increase in the proliferative capacity of
hepatocytes, representing a potentially
valuable target for future treatments.In both liver disease models the top hit
is mitogen-activated protein kinase
(MKK) 4. Of the seven currently known
MKKs, MKK4 (also known as SEK1) and
MKK7 (SEK2) are activators of c-Jun
N-terminal kinase (JNK) signaling, which
regulates essential cell functions such as
proliferation and survival (Haeusgen
et al., 2011). Mice deficient in MKK4 and
MKK7 exhibit defects in liver development
due to death and cell-cycle arrest of em-
bryonic liver progenitors (Nishina et al.,
1999; Wada et al., 2004). By dissecting
the function of MKK4 and MKK7 in hepa-
tocytes of adult mice, Wuestefeld et al.
shed new light on the regulation and func-
tion of JNK signaling in postnatal liver
regeneration and unexpectedly suggest
inhibition of MKK4 as a strategy for
improving or restoring it.
Inhibition of MKK4 has multiple benefi-
cial effects. First, it significantly acceler-ates hepatocyte proliferation, both in the
fumarylacetoacetate hydrolase-deficient
mouse model of subacute liver failure
and after chronic liver injury with carbon
tetrachloride. Second, MKK4-deficient
hepatocytes are protected from Fas-
mediated apoptosis. Finally, MKK4 defi-
ciency also decreases the severity of liver
fibrosis. This last finding underscores the
importance of hepatocyte cell cycle arrest
and death as triggers of liver cirrhosis.
At the molecular level, MKK4 knock-
down causes activation of JNK signaling.
This finding is unexpected, considering
that MKK4 is a JNK activator. As the un-
derlying mechanism the authors identify
compensatory activation of MKK7 using
a combinatorial gene knockdown strat-
egy: Concurrent knockdown of MKK7 in
MKK4-deficient hepatocytes abolishes
the phenotype of accelerated prolifera-
tion. Further investigations reveal that153, April 11, 2013 ª2013 Elsevier Inc. 283
Figure 1. MKK4 Inhibition Accelerates Hepatocyte Proliferation and
Tissue Regeneration
Liver injury frequently causes impaired hepatocyte replication and apoptosis,
leading to hepatic failure and death, or severe fibrosis. Inhibition of MKK4, as
demonstrated by Wuestefeld et al. (2013), accelerates the replication of
hepatocytes and prevents their apoptosis, thereby permitting successful
tissue regeneration.the proproliferative effect of
MKK7 activation is mediated
by JNK1 and its effectors
ATF2 and ELK1. These find-
ings are consistent with a
model in which MKK7 is the
principal activator of JNK
signaling (Haeusgen et al.,
2011). Furthermore, the find-
ings provide evidence for the
emerging concept of recip-
rocal regulation of MKK4
and MKK7 activity (Haeusgen
et al., 2011). Because MKK4
also activates p38 signaling,
which generally inhibits prolif-
eration, it would be inter-
esting to delineate the contri-
bution of p38 suppression to
the phenotypes observed in
MKK4-deficient hepatocytes.
The authors’ finding that
MKK4 deficiency renders
adult hepatocytes resistant
to apoptosis differs from
previous findings of sponta-
neous apoptosis of embry-
onic liver progenitors in
MKK4-deficientmice (Nishina
et al., 1999). In addition, sus-tained JNK activation, as observed in
MKK4-deficient hepatocytes, would have
been expected to be essential for Fas-
induced apoptosis (Corazza et al., 2006),
not to antagonize it. These ‘‘contradic-
tions’’ support the notion that the effects
of JNK signaling are highly cell-type and
context dependent (Seki et al., 2012).
The work by Wuestefeld et al. has
several exciting therapeutic implications.
Although MKK4 deletions can be found
in liver cancer, their data indicate that
MKK4 deficiency alone is insufficient to
cause hepatocyte proliferation or liver
cancer. Instead, MKK4 depletion acceler-
ates regeneration that has already been
initiated, making it more efficient. It also
protects dividing hepatocytes from pre-
mature death. Transient MKK4 inhibition
therefore has potential in the therapy of
acute liver failure (Figure 1). This would
require fast-acting MKK4 blockage to
facilitate restoration of a critical hepato-
cyte mass before aggravation of the284 Cell 153, April 11, 2013 ª2013 Elsevier Inillness to multiorgan failure (Ido et al.,
2011). For this, antisense oligonucleo-
tides could be used that reach hepato-
cytes and knock down targeted genes
within hours after intravenous injection
(Ng et al., 2012). Alternatively, specific
small-molecule inhibitors of MKK4 could
be developed.
Another finding of potentially great
impact is the ability of MKK4-deficient
hepatocytes to engraft and repopulate
mice after extended culture. Typically,
mouse hepatocytes lose their engraft-
ment potential after only 3–4 days in cul-
ture, but MKK4-deficient hepatocytes
could be transplanted even after 12 days
ex vivo. If this feature were replicated in
human cells, it would be particularly use-
ful for improving engraftment and post-
transplant expansion of hepatocyte-like
cells generated by in vitro differentiation
of pluripotent stem cells. In addition,
exposing MKK4-deficient hepatocytes to
growth factors may allow their in vitroc.expansion, a feat liver re-
searchers have been working
for decades to achieve.
It appears unlikely that
MKK4 would have been cho-
sen as a therapeutic target
based on hypotheses derived
from pre-existing studies.
The success of this study
once again underscores the
power of unbiased ‘‘blind’’
screens, particularly those
that can be carried out in vivo
in a clinically relevant system.
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